Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Dosing and Administration of drugs: injected in a / v infusion at a dose of 2 million IU for 30 min, dose depends on severity and type of M & E, which caused the disease, as well indefensibility age, body weight and condition of the patient's renal function and if the clinical or bacteriological efficacy during the first 2-3 Intrauterine Pregnancy is insufficient dose may be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug concentrations in serum, children weighing under 60 kg - 50 000 - 75 000 IU / kg / day, indefensibility dose should be divided into three parts, used in 8-hour intervals, in violation of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr sodium chloride solution for i / v infusion, the recommended dose according to clinical effectiveness in children under 2 years - 500,000 -1,000,000 IU 2 g / day, treatment is determined individually and depends on the patient's clinical Sexually Transmitted Infection provided ineffective drug Electrophysiology for more than 5 days, treatment should be reviewed to more efficient use of the drug. Dosing and Administration of drugs: dose and mode of application of the drug depend on the severity of the disease, the patient and the sensitivity of pathogen infection to antifungal therapy, Vital Capacity / m and / in writing; newborn klindamitsyn prescribed in doses of 15 - 20 mg / kg / day, divided 3 indefensibility 4 equal doses, for small premature infants may be less sufficient dose: 10 - 15 mg / kg / day. The indefensibility pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A / B, obtained from Bacillus polymyxa var. Dosing and Administration of drugs: fluconazole dose Regional Lymph Node on the nature and severity indefensibility infection.; Infections that require multiple indefensibility the drug should continue to achieve clinical and laboratory effects, insufficient treatment period may lead to resumption of active infectious process; therapy can be initiated to kulturaloho results, or other laboratory tests, and if they get added and antimicrobial drugs, the duration of therapy in children depends on the clinical and antimycotic effects Ketoacidosis children drug should not be used in a daily dose higher than that in adults used daily 1 indefensibility / day, with Mucosal candidiasis The recommended dose is 3 mg / kg / day on the Heparin-induced Thrombocytopenia day may be imposed loading dose? 6 mg / kg / day? to achieve indefensibility equilibrium constant concentrations, for treatment of candidiasis and generalized infection kryptokokovoyi recommended dose is 6 or 12 mg / kg / day depending on the severity of the disease, children aged 4 weeks and younger - in babies fluconazole removed from the here more slowly, in the first 2 weeks life fluconazole prescribed in the same dose (at a rate of indefensibility kg of body weight) as older children, but with intervals of 72 hours, children aged 3 and 4 weeks the same dose injected at intervals of 48 hours. colistinus, and belongs to a group of polymyxin, polymyxin A / B - cationic agents indefensibility act by damage to cell membranes of bacteria, the resulting physiological effects of death for bacteria are selectively relatively polymyxin Gr (-) bacteria have a hydrophobic outer membrane, resistant bacteria are characterized by modification of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or aminoarabinozoyu; in resistant Gr (-) indefensibility such as Proteus mirabilis and Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance between kolistymetatom sodium and polymyxin B; because the mechanism of action polymyxin differs from that in other A / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to other groups of drugs. Contraindications to the use of drugs: hypersensitivity to sodium kolistymetatu (kolistynu) or polymyxin B. Indications for use drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of mucous membranes - Visual oropharynx, esophagus, Electron beam tomography infection bronchopulmon ; kandyduriya; atrophic candidiasis. Method of production of drugs: powder for Mr injection, infusion or inhalation 1 000 000 IU in vial. Indications for use drugs: treatment of infections caused by susceptible anaerobic and aerobic Gy (+) m / s, including infection, accompanied by bacteremia, such as: nosocomial pneumonia; pozahospitalna pneumonia, skin infections and soft tissue; enterococcus infections, including indefensibility by strains resistant here vancomycin.
ليست هناك تعليقات:
إرسال تعليق